WELL:SW:SW-HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (CHF)

ETF | Others |

Last Closing

USD 6.403

Change

+0.09 (+1.47)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
WELL:SW
Relative Returns (From:    To: 2025-01-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.03 (+0.22%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.07 (+0.32%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.01 (+0.02%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-2.00 (-0.03%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+4.00 (+0.22%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+10.00 (+0.40%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.35 (+0.43%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

-0.08 (-0.07%)

USD 130,595.12B

ETFs Containing WELL:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.43% 89% A- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.43% 89% A- 85% B
Trailing 12 Months  
Capital Gain 5.17% 30% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.17% 28% F 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.56% 9% A- 13% F
Dividend Return -1.56% 9% A- 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.98% 68% D+ 72% C
Risk Adjusted Return -26.03% 9% A- 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CHF)

Quarterly Financials (CHF)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.